Compare Nokia Corp (NOK) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Zimmer Biomet Holdings Inc — how do they compare? Nokia Corp trades at $10.36 (market cap $56.99B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Nokia Corp is far larger — about 3.4× Zimmer Biomet Holdings Inc's market cap, and Nokia Corp pays the higher dividend (1.61%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NOK | ZBH | |
|---|---|---|
Market Cap | $56.99B | $16.95B |
Volume | 69,968,204 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $16.83 | $103.98 |
52-Week Low | $5.25 | $79.58 |
Typical Hold Time | 66 Days | 89 Days |
Enterprise Value | $55.01B | $24.02B |
Dividend Yield | 1.61% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.14, down 4.52% over 24 hours, with a bearish technical signal. The stock shows mixed earnings, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue has stabilized around $20B annually, with a net income margin of 3.47% in 2025. Analyst consensus is bullish, with a $17.50 price target, supported by recent partnerships in AI and satellite communications.
The outlook is cautiously optimistic, driven by AI infrastructure demand and strategic alliances, but risks include competitive pressures and volatile cash flows. Upside potential exists if execution on growth initiatives improves profitability, while downside risks stem from macroeconomic headwinds and execution missteps.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
